Spigel et al. [14] conducted a phase-III randomized clinical trial using nanoparticle albumin-bound paclitaxel in combination with carboplatin induction followed by nanoparticle albumin-bound paclitaxel for maintenance therapy in squamous non-small cell lung cancer (NSCLC) patients. Here, ALB is linked to non-small cell squamous lung carcinoma.